These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 30016491)
1. Implementing a dengue vaccination programme-who, where and how? E Clapham H; A Wills B Trans R Soc Trop Med Hyg; 2018 Aug; 112(8):367-368. PubMed ID: 30016491 [TBL] [Abstract][Full Text] [Related]
2. Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case study. Turner HC; Wills BA; Rahman M; Quoc Cuong H; Thwaites GE; Boni MF; Clapham HE Trans R Soc Trop Med Hyg; 2018 Aug; 112(8):369-377. PubMed ID: 29982700 [TBL] [Abstract][Full Text] [Related]
3. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia. Lee JS; Lourenço J; Gupta S; Farlow A Vaccine; 2018 Apr; 36(17):2346-2355. PubMed ID: 29573874 [TBL] [Abstract][Full Text] [Related]
4. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials. de Silva AM; Harris E Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716891 [TBL] [Abstract][Full Text] [Related]
7. Dengue: Status of current and under-development vaccines. Redoni M; Yacoub S; Rivino L; Giacobbe DR; Luzzati R; Di Bella S Rev Med Virol; 2020 Jul; 30(4):e2101. PubMed ID: 32101634 [TBL] [Abstract][Full Text] [Related]
8. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination. Whitehead SS; Subbarao K Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716894 [TBL] [Abstract][Full Text] [Related]
9. The Optimal Age of Vaccination Against Dengue with an Age-Dependent Biting Rate with Application to Brazil. Maier SB; Massad E; Amaku M; Burattini MN; Greenhalgh D Bull Math Biol; 2020 Jan; 82(1):12. PubMed ID: 31933012 [TBL] [Abstract][Full Text] [Related]
10. Dengue vaccine: WHO position paper, September 2018 - Recommendations. Vaccine; 2019 Aug; 37(35):4848-4849. PubMed ID: 30424888 [TBL] [Abstract][Full Text] [Related]
12. Optimal dengue vaccination strategies of seropositive individuals. Shim E Math Biosci Eng; 2019 Feb; 16(3):1171-1189. PubMed ID: 30947414 [TBL] [Abstract][Full Text] [Related]
13. Vaccines licensed and in clinical trials for the prevention of dengue. Torresi J; Ebert G; Pellegrini M Hum Vaccin Immunother; 2017 May; 13(5):1059-1072. PubMed ID: 28281864 [TBL] [Abstract][Full Text] [Related]
14. Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus? Valdés I; Lazo L; Hermida L; Guillén G; Gil L Front Immunol; 2019; 10():1956. PubMed ID: 31507591 [TBL] [Abstract][Full Text] [Related]
15. The optimal age of vaccination against dengue in Brazil based on serotype-specific forces of infection derived from serological data. Maier SB; Massad E; Amaku M; Burattini MN; Greenhalgh D Math Med Biol; 2021 Mar; 38(1):1-27. PubMed ID: 32671383 [TBL] [Abstract][Full Text] [Related]
16. Dengue infection and advances in dengue vaccines for children. Halstead SB; Dans LF Lancet Child Adolesc Health; 2019 Oct; 3(10):734-741. PubMed ID: 31378686 [TBL] [Abstract][Full Text] [Related]